This article is more than 5 years old. Information may no longer be current.
Hormone therapy linked with decreased fracture risk for postmenopausal women
Click Here to Manage Email Alerts
Among postmenopausal women, investigators found the risk of fracture decreased with the use of hormone therapy. Moreover, the findings were particularly true for women with the highest genetic risk for fracture and low bone mineral density.
Using two, weighted, genetic risk scores based on 16 fracture-associated variants and 50 bone mineral density variants, investigators studied 9,922 genotyped white postmenopausal women with data in the Women’s Health Initiative Hormone Therapy randomized trials. The main effects of the genetic risk scores and interaction with hormone therapy on fracture risk were estimated with Cox regression. The relative risk due to interaction was estimated for measurement of the additive interaction and a case-only approach was used to test for multiplicative interaction.
Results showed both the fracture-associated variants and the bone mineral density variants correlated with fracture. Investigators noted for either of the genetic risk scores, there was no evidence of multiplicative interaction. A significant additive interaction was observed for the genetic risk scores and hormone therapy.
“The joint effect of randomization to placebo and high genetic susceptibility on total fracture risk was larger than expected from the sum of the individual effects,” the researchers wrote. – by Monica Jaramillo
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts